|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-cat = β-catenin 1; CI = confidence interval; PTC = papillary thyroid carcinoma; ROC = receiver operating characteristic.
|
29498921 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
XRCC1 T-77C polymorphism affects the genetic susceptibility for PTC development in men, the specific combination of XRCC1 haplotypes correlates with RET/PTC incidence, CDKN1B Val109Gly significantly influences the risk of developing PTC regardless of gender and in PTC cases, selected genotypes of TP53 Arg72Pro and ATM Asp1853Asn were significantly associated with monitored tumour characteristics.
|
27314298 |
2016 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
With the analyses of DNA rearrangement sites of RET gene fusions in PTC, signatures of chromosome translocations related to RET fusion events were also depicted.
|
29144541 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed that RET is required for cell survival in medullary (MTC) but not papillary thyroid carcinoma (PTC) cells.
|
27872141 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We report the successful validation of a combined gene expression profiling and tissue microarray approach to papillary thyroid carcinoma (PTC) biomarker identification.
|
18261626 |
2008 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We report the conjugation of the natural lipid squalene (SQ) with a small interfering RNA (siRNA), against the junction oncogene RET/PTC1, usually found in papillary thyroid carcinoma (PTC).
|
21561161 |
2011 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We report a FAP-associated CMVPTC tumor with atypically aggressive features harboring a RAS mutation and review the molecular mechanisms associated with this interesting PTC subtype.
|
24702198 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We report a case of synchronous MTC and PTC in a patient with germline RET mutation, and investigate the molecular pathogenesis of these two tumors.
|
20369307 |
2010 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We previously reported high frequency (6/11) of rearrangement of the RET protooncogene in Chinese PTCs.
|
11216646 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated whether a specific type of RET/PTC rearrangement was induced by X-rays in vivo and in vitro.
|
10656692 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that a subset of HCTs represent PTC with clinical, histological, and immunohistochemical features based on specific molecular events. ret/PTC gene rearrangements give rise to novel oncogenes that are unique to PTC.
|
10690905 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We here report on RET protein immunoreactivity in paraffin-embedded thyroid samples from 30 patients with papillary thyroid cancer who received radiation treatment during childhood for benign conditions at Michael Reese Hospital in Chicago, and in 34 patients identified from the tumor registry as having papillary thyroid cancer with no history of therapeutic radiation.
|
12161537 |
2002 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We have studied the expression of the RET encoded protein in 127 papillary thyroid carcinomas by immunohistochemistry using a polyclonal antibody against the tyrosine-kinase domain of the RET protein.
|
11720878 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have previously reported a high percentage (86.7%) of RET-positive papillary thyroid cancers in a cohort of individuals exposed to external radiation of the head and neck area before the age of 16.
|
16487015 |
2006 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma.
|
24510380 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have developed a dual-color FISH approach to detect RET/PTC rearrangements in interphase nuclei of thyroid lesions.
|
10773666 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have correlated the presence of specific SNPs and the rare RET V804M mutation to MTC, C-cell hyperplasia (CCH), and PTC.
|
21134561 |
2010 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have analyzed RET rearrangements in post-Chernobyl papillary thyroid carcinomas (n = 29), follicular thyroid adenomas (n = 2), and follicular thyroid carcinoma (n = 1) by interphase fluorescence in situ hybridization (FISH) analysis on paraffin-embedded tissue sections.
|
15356021 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We found a significant association between the localization of RET mutations and the expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid cancer).
|
28181547 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We exploited the MassARRAY (MA) genotyping platform to develop the "PTC-MA assay", which allows the simultaneous detection of 13 hotspot mutations, in the BRAF, KRAS, NRAS, HRAS, TERT, AKT1, PIK3CA, and EIF1AX genes, and six recurrent genetic rearrangements, involving the RET and TRK genes in papillary thyroid cancer (PTC).
|
29214440 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined the expression of RET/PTC-1, -2, and -3 in human thyroid microcarcinomas and clinically evident PC to determine its role in early stage vs. developed PC and to examine the diversity of RET/PTC in multifocal disease.
|
9814501 |
1998 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We examined the expression of ret/PTC in 99 German papillary thyroid carcinomas, including two recently described new variants of ret/PTC3 and identified eight ret/PTC-positive tumours (8%) but none with the new variants.
|
9528832 |
1998 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We evaluated RET G691S (rs1799939), L769L (rs1800861), and S904S (rs1800863) polymorphisms to elucidate their possible role as risk factors in papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC).
|
25736215 |
2015 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We did a comprehensive screen for 548 known and putative fusion genes in 27 samples of thyroid tumors and three positive controls-one thyroid cancer cell line (TPC-1) and two PTCs with known CCDC6-RET (alias RET/PTC1) fusion gene, using this microarray.
|
22961909 |
2012 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We detected RET transcription in approximately 85% of the PTCs including follicular variants and in isolated cells of the same tissues, but not in nonmalignant thyroid tissue.
|
11279350 |
2000 |